59 results about "Prostate cancer" patented technology

The present disclosure relates to methods of treating PTEN-deficient metastatic hormone- sensitive prostate cancer (mHSPC) in patients in need thereof, the methods comprising administering to the patients a combination comprising capivasertib or a pharmaceutically acceptable salt thereof; and abiraterone or an ester prodrug thereof, or a pharmaceutically acceptable salt thereof.

The present invention provides methods for the detection of aggressive prostate cancer, and methods for detecting aggressive prostate cancer based on comparisons to a mixed control population of subjects with non-aggressive prostate cancer or not having prostate cancer.

This disclosure provides a method for detecting prostate cancer in human subjects, wherein a Cu-64 PSMA I&T composition of about 7 mCi to about 9 mCi is administered to the human subject, images are obtained 1 hour to 4 hours after administration, and wherein the obtained images maintain acceptable image quality for up to 4 hours after administration.

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170

This invention relates to biomarkers and their applications for predicting the risk of prostate cancer induced by triclosan, belonging to the fields of environmental health and tumor biology. This invention systematically identifies oncogenes CHRM5, PLK1, ALB, and TOP2A associated with triclosan exposure and constructs a predictive model for the risk of prostate cancer induced by triclosan using machine learning methods. Therefore, this invention provides novel biomarkers and potential therapeutic targets for predicting the risk of prostate cancer induced by triclosan.

This application belongs to the field of anticancer drug technology, specifically relating to a prostate cancer-targeted verteporfen, its preparation method, and its application. The prostate cancer-targeted verteporfen has the chemical formula shown as Formula I in the specification. The prostate cancer-targeted verteporfen provided in this application has good water solubility and targeting properties, enabling effective delivery to the target site. Combined with ultrasound physical stimulation, it can achieve in-situ generation of reactive oxygen species in the tumor, releasing verteporfen and reactive oxygen species, effectively enhancing the killing effect on tumor cells.

The application belongs to the technical field of biological medicine, and particularly relates to a kit for early screening of prostate cancer, a preparation method and application thereof. The kit for early screening of prostate cancer comprises primer pairs for detecting hsa_circ_0058040, hsa_circ_0096498 and hsa_circ_0000994. The application finds that the three circRNAs have expression differences in serum of healthy people and prostate cancer patients through high-throughput sequencing and experimental verification, and the three circRNAs are applied to preparation of the kit. The content of hsa_circ_0058040, hsa_circ_0096498 and hsa_circ_0000994 in serum can be detected through real-time fluorescent quantitative PCR technology, and the kit has high diagnostic value and wide application prospect.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

The application provides a dual-mode immune probe based on a titanium carbide SERS substrate and rare earth doped sodium yttrium fluoride nanoparticles and a preparation method and application thereof, and comprises a titanium carbide / molybdenum disulfide composite immune substrate and a NaYF4:Yb,Er immune probe, wherein 78% Y, 20% Yb and 2% Er are contained in the NaYF4:Yb,Er, and the preparation method comprises the following steps: (S10) preparing titanium carbide powder by using an acid etching method; (S20) preparing a titanium carbide / molybdenum disulfide composite immune substrate; and (S30) preparing a NaYF4:Yb,Er immune probe, and the application is suitable for application in detection of prostate cancer, and the detection has high efficiency, high accuracy and high sensitivity, and is suitable for clinical popularization and application.

Compositions and methods are described herein that are useful for the detection of prostate cancer progression by determining the expression levels of genes associated with metastatic PCa. Based on the expression of IL-6, SELE, FOSB, NRK, NFRB2, FOXP3, ARG1, CEBPDP, TNFα, ADAMTS4, PENK, FOSL1, DUSP1, ACTA1, AGT, ATF3, CDK1, CXCL8, SELP, VCAN, TFP12, or NR4A3 genes or any combination thereof, treatment of PCa with SELE agonists, TNFα antagonists, and / or immune checkpoint inhibitors (ICIs) are shown to be effective.

The present application relates to the use of a miRNA combination in the preparation of a non-invasive diagnostic reagent for prostate cancer. Specifically, the present application provides the use of a miRNA combination as a diagnostic marker for prostate cancer, which includes multiple of hsa-miR-21-5p, hsa-miR-100-5p, hsa-miR-141-3p, hsa-miR-375-5p, and hsa-let-7f-5p. The expression levels of the miRNA combination in serum are detected by a method based on rolling circle amplification and single-strand cleavage protein, and a diagnostic model is constructed by combining a machine learning algorithm, significantly improving the diagnostic accuracy of prostate cancer. The method of the present application is a non-invasive, rapid, accurate and low-cost method for detecting prostate cancer, and has a broad application prospect.

The present disclosure provides a vaccine against cancers that express MHC-II. That includes hormone positive breast cancers and some prostate cancers and melanoma. It is possible, based on a genomic test of the individual, to either (1) design a personal vaccine consisting of a polytope based on epitopes from the TAA that in most cases display on MHC-II and not on MHC-I, or (2) select previously manufactured sequences based on epitopes from the TAA as constituents of the vaccine, such that the cancer after vaccination will reveal itself to the immune system and get eradicated while there are little side effects in that the vaccine will not make the immune system harm the healthy tissue.

Provided are compositions and methods for treating cancers, in particular those characterized with PSMA expression such as prostate cancer. The compositions include a conditionally-activatable XTENylated Protease-Activated bispecific T Cell Engager targeting PSMA (PSMA-XPAT) that remain inactive until activated by proteases present in tumor microenvironment. The PSMA-XPAT exhibited exceptional safety profiles even at high doses and were efficacious in cancer patients resistant to even multiple lines of prior therapies.

The application relates to application of PUS1 in improving sensitivity of enzalutamide to prostate cancer treatment. Through bioinformatics analysis and a series of in-vivo and in-vitro experiments, the application first discovers and determines the key role of the expression level of PUS1 in reducing the sensitivity of enzalutamide in treating prostate cancer, and deeply studies the mechanism, and determines that the PUS1 promotes enzalutamide resistance of prostate cancer in dependence on the Psi modification activity. The application enriches the related mechanism of drug resistance generation and regulation in the process of enzalutamide in treating prostate cancer, provides sufficient scientific basis and theoretical basis for exploring new prostate cancer diagnosis, prognosis judgment and treatment molecular target, and developing new targeted drugs, and has important social value and scientific significance.

A method for needle position optimization for prostate brachytherapy for use with a radiation delivery device configured to use a plurality of needles inserted into a prostate of a patient includes obtaining imagery of the prostate of the patient, generating a needle pool for prostate brachytherapy treatment of the patient based on the imagery of the prostate of the patient, and determining at a computing device an optimum prostate brachytherapy treatment plan for the patient by iteratively removing needles from the needle pool by forming and computationally solving a convex optimization problem wherein the convex optimization problem uses a quadratic dosimetric penalty function, dwell time regularization by total variation, and block sparsity regularization term.

The application provides a multifunctional nano drug delivery system based on iron-doped MOF and a preparation method and application thereof. The system comprises: an Fe / MOF core loaded with a chemotherapeutic drug and an HO-1 inhibitor; a PDA coating layer coated on the surface of the Fe / MOF core for providing near-infrared light heat conversion capability and surface modification interface; and E3 aptamer covalently coupled on the PDA coating layer, constituting a synergistic nano platform with active targeting, pH / NIR dual-responsive drug release, chemical kinetics therapy, ferroptosis sensitization, photothermal therapy and immune regulation functions. The nano system can realize efficient accumulation at the tumor site through active targeting mediated by E3 aptamer, and controllably release drugs under an acidic microenvironment or near-infrared light. A new strategy for multi-mechanism synergistic treatment is provided to overcome the multiple drug resistance and immunosuppression of mCRPC, and has important clinical application prospects.

This invention discloses indole-fused hydrogenated morpholino compounds, their preparation methods, and applications, belonging to the technical fields of fluorescent materials and antitumor compounds. Using enamine ketones and amines as reaction substrates, a series of indole-fused hydrogenated morpholino compounds with different substituents were synthesized in highly polar solvents via the Stork enamine reaction and intramolecular acylation reaction. These compounds exhibit fluorescence wavelengths in the range of 430-700 nm and show certain inhibitory activity against lung cancer A549, breast cancer MDA-MB-231, colon cancer HCT116, liver cancer HepG2, and prostate cancer DU145, providing more options for the preparation of tumor drugs.

The present invention relates to methods for predicting the progression of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC), in an individual. The invention employs gene expression profiling combined with predictive modeling to assess the likelihood of overall survival and biochemical recurrence following treatment.

The invention provides methods and compositions for treating cancer, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer).

Diagnosis of prostate cancer often involves invasive measures, such as biopsies, in which tissue is removed and graded by a pathologist. Non-invasive measures, such as multi-parametric MRI, can be used to examine lesions and grade them using the PI-RADS scoring scale; however, achievable image resolution is limited by motion. A new paradigm, magnetic resonance histopathology (MRH), is disclosed, which aims to evaluate tissue texture at sub-millimeter resolution through a fast clinical acquisition process. The ability of MRH to identify cancerous tissue in the prostate through computer simulation analysis is demonstrated, reproducing the MRH measurement process on a set of high-resolution, histology slides annotated by pathologists (2, 4, 6, 8, 10, 12, 14). A dataset of spectral intensities (20) at sub-millimeter wavelengths is created, and a deep learning model (22) trained to classify the spectral data is based on normal or tumor tissue. A set of spatial frequencies is identified, which is used to optimize diagnostic capability under the constraint of limited acquisition time. In addition to single-region classification, the disclosed method and architecture integrate spatial context and local information, the inclusion of which improves model performance and denoises inference results. In addition to algorithms for estimating the physical length scale of lesions identified by the model, the trained model is demonstrated to be applied to unlabeled high-resolution 3D MRI data.

The application provides a kind of bionic nano immune base material and its preparation method and application, wherein the bionic nano immune base material includes PDMS@AgNPs@ZIF-67 bionic immune base and gold nanorod immune probe, its preparation method includes the following steps: (S10) the preparation of ZIF-67 nano material;(S20) the preparation of PDMS@AgNPs@ZIF-67 bionic polymer material;(S30) the preparation of PDMS@AgNPs@ZIF-67 bionic immune base material;And (S40) the synthesis of gold nanorod immune probe, by studying the construction of SERS base on MOFs modified bionic base, which has both synergistic effect, and has the ability of anchoring molecule, improve the efficiency and sensitivity of prostate cancer examination, it has important significance to improve the detection efficiency of PSA.

The application discloses application of a nitroreductase inhibitor in preparation of a drug for treating prostate cancer, and relates to the technical field of tumor treatment. The application provides application of the nitroreductase inhibitor in preparation of a drug for preventing and / or treating prostate cancer in combination with flutamide, the nitroreductase inhibitor can inhibit metabolism of flutamide, and elimination of escherichia coli can improve the antitumor effect of flutamide.

The present disclosure relates to compounds, pharmaceutical compositions, and methods of using the compounds and compositions to restore activity of von Hippel Lindau tumor suppressor protein (pVHL). Such compounds and compositions can be useful in, for example, the treatment of cancer (e.g.. a sarcoma, a carcinoma, a head-and-neck cancer, hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)) and von Hippel-Lindau disease (VHLD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods and apparatus for computer-aided prostate condition diagnosis are disclosed. An example computer-aided prostate condition diagnosis apparatus includes a memory to store instructions and a processor. The example processor can detect a lesion from an image of a prostate and generate a mapping of the lesion from the image to a sector mapping, the generating the mapping of the lesion including identifying a depth region of the lesion, where the depth region indicates a location of the lesion along a depth axis. The processor can also provide the sector mapping including a representation of the lesion within the prostate mapped from the image to the sector mapping.

Methods, systems, and kits for the diagnosis, prognosis and the determination of cancer progression of prostate cancer in a subject are disclosed. In particular, the disclosure relates to the use of immune cell-specific gene expression in determining prognosis and identifying individuals in need of treatment for prostate cancer who will be responsive to radiation therapy.

The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer.